| Revenue Growth | Total revenue up 24% to $102.9M; TissueCypher revenue primary driver. |
|---|---|
| Mgmt Confidence | High confidence in core drivers; raised full-year midpoint guidance by $20M. |
| Demand Visibility | TissueCypher 15% penetrated; DecisionDX-Melanoma fifth quarter exceeding 10,000 reports. |
| Margin Trends | Adjusted gross margin steady at 77%; efficiencies offsetting higher lab costs. |
| Op. Leverage | Scaling lab headcount with volume but achieving incremental efficiency gains. |
| Pricing Power | ASP improvements in core products; seeking crosswalk pricing for IDDX-AD. |
| Vol vs Price | Volume-led growth in TissueCypher (47%); mid-single digit growth in Melanoma. |
| Segment Growth | TissueCypher volume up 47%; DecisionDX-Melanoma volume up 5% year-to-date. |
| New Clients | Adding new ordering clinicians for TissueCypher; 100-person sales teams sufficient. |
| Capex & Debt | Ended quarter with $278M cash; $19.7M net cash from operations. |
| Regulatory | CMS proposed gapfill for ADTX; SCC Medicare coverage not expected until 2028. |
| Commentary | Focusing on clinical evidence to drive adoption in under-penetrated Barrett's market. |
| New Launches | Integrating Esopredict acquisition to provide answers when TissueCypher samples fail. |
Growth
Revenue grew 24% to $102.9M; TissueCypher volumes surged 47% to 15,574 reports.
Outlook
Raised 2026 revenue guidance to $385M-$395M; positive adjusted EBITDA expected for 2027.
Risks
Management pivoted on specific SCC Medicare coverage timelines, pushing recovery expectations into 2028.
The company's earnings call, NASDAQ: CSTL, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Castle Biosciences Inc: key numbers
- Share price
- $32.75Close, Nov 16
- Market cap
- $1.01B
- Shares outstanding
- 30.82MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Castle Biosciences Inc
All →Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $112K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 3,195 shares of Castle Biosciences Inc at $35.07 a share, worth $112K in total on Nov 11, 2026. Shares held after the trade: 32,737 (-8.9%).
- Value
- $112K
- Shares
- 3,195
- Price
- $35.07
- Role
- Chief Commercial Officer
- Holding change
- -8.9%
- Trade date
- Nov 11, 2026
Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $207K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 6,116 shares of Castle Biosciences Inc at $32.67 to $35.04 a share (average $33.77) in 2 transactions, worth $207K in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 32,737 (-8.0%).
- Value
- $207K
- Shares
- 6,116
- Average price
- $33.77
- Role
- Chief Commercial Officer
- Holding change
- -8.0%
- Trade date
- Nov 9, 2026 to Nov 11, 2026
Castle Biosciences Q3 2026 Results: Net Loss of $4.1M, Loss Widens
Castle Biosciences reported net revenues of $102.9 million for the third quarter of 2026, up from $83.0 million in 2025. Despite the revenue growth, the company realized a net loss of $4.1 million for the quarter, primarily driven by increased operating expenses in selling, general, and administrative functions.
- Key figure
- Net loss $4.1M
Castle Biosciences Financial Results
Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.
- Term
- Q3 2026
“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”
Derek Maetzold, president and chief executive officer of Castle Biosciences
Castle Biosciences Pres. & Chief Exec. Officer Derek J. Maetzold Sells $523K of Stock
Derek J. Maetzold, Pres. & Chief Exec. Officer, sold 14,496 shares of Castle Biosciences Inc at $36.01 to $36.81 a share (average $36.10) in 6 transactions, worth $523K in total on Nov 2, 2026. Shares held after the trade: 1,396 (-18.9%).
- Value
- $523K
- Shares
- 14,496
- Average price
- $36.10
- Role
- Pres. & Chief Exec. Officer
- Holding change
- -18.9%
- Trade date
- Nov 2, 2026
Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $240K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 6,578 shares of Castle Biosciences Inc at $35.58 to $36.62 a share (average $36.42) in 2 transactions, worth $240K in total on Oct 28, 2026. Shares held after the trade: 38,853 (-12.1%).
- Value
- $240K
- Shares
- 6,578
- Average price
- $36.42
- Role
- Chief Commercial Officer
- Holding change
- -12.1%
- Trade date
- Oct 28, 2026